Temozolomide (brand name Temodar®) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumour. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). Temodar is marketed by Schering Corporation, which also markets other well-known prescription drugs such as Clarinex, Nasonex, Levitra, Cipro, Vytorin, Diprolene, Elocon and Lotrisone.

Indications

Glioblastoma multiforme: for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as manitenance treatment.
Anaplastic astrocytoma: for the treatment of adult patients with refractory anaplastic atrocytoma (ie. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine).
Unlabeled uses: Metastatic melanoma.

Dosage Forms

Temozolomide is available in the United States in 5mg, 20mg, 100mg, & 250mg capsules.

Read more at Wikipedia.org

• [List your site here Free!]

Temozolomide vs. dacarbazine in stage IV metastatic melanoma
From Journal of Drugs in Dermatology, 11/1/05

This study is currently recruiting patients. Sponsors and Collaborators. Schering-Plough European Organization for Research and Treatment of Cancer. The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme under laying resistance, is a more effective treatment of metastatic melanoma than single agent dacarbazine.

Study ID Numbers: P03267

ClinicalTrials.gov Identifier: NCT00091572

Return to Temozolomide

Home

Contact

Resources

Exchange Links

ebay